Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition

Marine Drugs

Volumn 9, Issue 11, 2011, Pages 2397-2408

  Ponder, Jessica ^a   Yoo, Byong Hoon ^a   Abraham, Adedoyin D ^a   Li, Qun ^a   Ashley, Amanda K ^b   Amerin, Courtney L ^b   Zhou, Qiong ^a   Reid, Brian G ^a   Reigan, Philip ^a   Hromas, Robert ^c   Nickoloff, Jac A ^b   LaBarbera, Daniel V ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; METNASE; NEOAMPHIMEDINE; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; IC 50; IN VITRO STUDY; INHIBITION KINETICS;

EID: 82655178859     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md9112397     Document Type: Article

References (34)

1. Champoux, J.J. DNA Topoisomerases: Structure, Function and Mechanism. Annu. Rev. Biochem. 2001, 70, 369-413. (Pubitemid 32662215)
2. Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9, 338-350.
3. Nitiss, J.L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 2009, 9, 327-337.
4. PDB ID: 1ZXM. Wei, H.; Ruthenburg, A.J.; Bechis, S.K.; Verdine, G.L. Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase. J. Biol. Chem. 2005, 280, 37041-37047.
5. Osheroff, N.; Zechiedrich, E.L.; Gale, K.C. Catalytic function of DNA topoisomerase II. BioEssays 1991, 13, 269-273.
6. Williamson, E.A.; Rasila, K.K.; Corwin, L.K.; Wray, J.; Beck, B.D.; Severns, V.; Mobarak, C.; Lee, S.H.; Nickoloff, J.A.; Hromas, R. The SET and transposase domain protein Metnase enhances chromosome decatenation: Regulation by automethylation. Nucleic Acids Res. 2008, 36, 5822-5831.
7. Wray, J.; Williamson, E.A.; Royce, M.; Shaheen, M.; Beck, B.D.; Lee, S.H.; Nickoloff, J.A.; Hromas, R. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells. PLoS One 2009, 4, e5323.
8. Wray, J.; Williamson, E.A.; Sheema, S.; Lee, S.H.; Libby, E.; Willman, C.L.; Nickoloff, J.A.; Hromas, R. Metnase mediates chromosome decatenation in acute leukemia cells. Blood 2009, 114, 1852-1858.
9. Marshall, K.M.; Matumoto, S.S.; Holden, J.A.; Concepcion, G.P.; Tasdemir, D.; Ireland, C.M.; Barrows, L.R. The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine. Biochem. Pharmacol. 2003, 66, 447-458. (Pubitemid 36937030)
10. Guzman, F.S.D.; Carte, B.; Troupe, N.; Faulkner, D.J.; Harper, M.K.; Concepcion, G.P.; Mangalindan, G.C.; Matsumoto, S.S.; Barrows, L.R.; Ireland, C.M. Neoamphimideine: A New Pyridoacridine Topoismerase II Inhibitor Which Cantenates DNA. J. Org. Chem. 1999, 64, 1400-1402. (Pubitemid 29098595)
11. Bender, R.P.; Jablonksy, M.J.; Shadid, M.; Romaine, I.; Dunlap, N.; Anklin, C.; Graves, D.E.; Osheroff, N. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. Biochemistry 2008, 47, 4501-4509. (Pubitemid 351522100)
12. Wu, C.C.; Li, T.K.; Farh, L.; Lin, L.Y.; Lin, T.S.; Yu, Y.J.; Yen, T.J.; Chiang, C.W.; Chan, N.L. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 2011, 333, 459-462.
13. Classen, S. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl. Acad. Sci. USA 2003, 100, 10629-10634. (Pubitemid 37140080)
14. Baird, C.; Harkins, T.; Morris, S.; Lindsley, J. Topoisomerase II drives DNA transport by hydrolyzing one ATP. Proc. Natl. Acad. Sci. USA 1999, 96, 13685-13690.
15. Maxwell, A.; Costenaro, L.; Mitelheiser, S.; Bates, A.D. Coupling ATP hydrolysis to DNA strand passage in type IIA DNA topoisomerases. Biochem. Soc. Trans. 2005, 33, 1460-1464. (Pubitemid 41779715)
16. Lanzetta, P.A.; Alvarez, L.J.; Reinach, P.S.; Candia, O.A. An improved assay for nanomole amounts of inorganic phosphate. Anal. Biochem. 1979, 100, 95-97. (Pubitemid 10157636)
17. Chene, P.; Rudloff, J.; Schoepfer, J.; Furet, P.; Meier, P.; Qian, Z.; Schlaeppi, J.M.; Schmitz, R.; Radimerski, T. Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem. Biol. 2009, 9, 1.
18. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234. (Pubitemid 43336035)
19. Beck, W.T.; Danks, M.K.; Wolverton, J.S.; Kim, R.; Chen, M. Drug resistance associated with altered DNA topoisomerase II. Adv. Enzyme Regul. 1993, 33, 113-127.
20. Matsumoto, Y.; Kunishio, K.; Nagao, S. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line. J. Neurooncol. 1999, 45, 37-46. (Pubitemid 30142439)
21. Shapiro, P.S.; Whalen, A.M.; Tolwinski, N.S.; Wilsbacher, J.; Froelich-Ammon, S.J.; Garcia, M.; Osheroff, N.; Ahn, N.G. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol. Cell. Biol. 1999, 19, 3551-3560. (Pubitemid 29193814)
22. Marshall, K.M.; Andjelic, C.D.; Tasdemir, D.; Concepcion, G.P.; Ireland, C.M.; Barrows, L.R. Deoxyamphimedine, a pyridoacridine alkaloid, damages DNA via the production of reactive oxygen species. Mar. Drugs 2009, 7, 196-209.
23. Matsumoto, S.S.; Haughey, H.M.; Schmehl, D.M.; Venables, D.A.; Ireland, C.M.; Holden, J.A.; Barrows, L.R. Makaluvamines vary in ability to induce dose-dependent DNA cleavage via topoisomerase II interaction. Anticancer Drugs 1999, 10, 39-45. (Pubitemid 29150179)
24. Rybenkov, V.V.; Ullsperger, C.; Vologodskii, A.V.; Cozzarelli, N.R. Simplification of DNA topology below equilibrium values by type II topoisomerases. Science 1997, 277, 690-693. (Pubitemid 27373915)
25. Discovery Studio, version 2.5.5; Accelrys Inc.: San Diego, CA, USA, 2009.
26. LaBarbera, D.V.; Bugni, T.S.; Ireland, C.M. The Total Synthesis of Neoamphimedine. J. Org. Chem. 2007, 72, 8501-8505. (Pubitemid 350012865)
27. Lee, S.H.; Oshige, M.; Durant, S.T.; Rasila, K.K.; Williamson, E.A.; Ramsey, H.; Kwan, L.; Nickoloff, J.A.; Hromas, R. The SET domain protein Metnase mediates foreign DNA integration and links integration to nonhomologous end-joining repair. Proc. Natl. Acad. Sci. USA 2005, 102, 18075-18080. (Pubitemid 41798504)
28. Quantity One; BioRad Laboratories Inc.: Hercules, CA, USA, 2009.
29. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112. (Pubitemid 20213250)
30. SoftMax Pro, version 4.8; Molecular Devices LLC: Sunnyvale, CA, USA, 2004.
31. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
32. Prism, version 5.0.3; GraphPad Software Inc: La Jolla, CA, USA, 2007.
33. Brooks, B.R.; Brooks, C.L., 3rd; Mackerell, A.D., Jr.; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 2009, 30, 1545-1614.
34. Montes, M.; Miteva, M.A.; Villoutreix, B.O. Structure-based virtual ligand screening with LigandFit: pose prediction and enrichment of compound collections. Proteins 2007, 68, 712-725. (Pubitemid 47068310)